Shanti Therapeutics

Shanti Therapeutics is a clinical-stage biotechnology company focused on developing novel applications for MDMA (3,4-methylenedioxymethamphetamine) in the treatment of acute and chronic pain. A subsidiary of Pegasus Mercantile (formerly Global Wellness Strategies), the company is pioneering the use of entheogens to modulate the psychosocial components of pain, particularly in peri-operative settings. Shanti's lead program involves a proprietary formulation of MDMA designed to increase pain tolerance thresholds, with clinical trials conducted in Australia. The company leverages strategic partnerships with specialized CROs and manufacturers to advance its pipeline of psychedelic-based therapeutics for pain management and mental health.